March 26, 2019

Sometimes our obsession with clinically proven data can get in the way of patient care. We can see that this week in an article about the official indication for the dual SGLT-1/2 inhibitor sotagliflozin. To find out what our patients may end up missing, check out our article #2.

Dave Joffe

Editor-in-chief